5/22/2013

GlaxoSmithKline will work in partnership with HHS' Biomedical Advanced Research and Development Authority to develop new antibiotics for drug-resistant pathogens and diseases that could be used as weapons. GSK will receive $40 million initially and up to $200 million if the deal is renewed.

Full Story:
Reuters, Bloomberg

Related Summaries